Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | $2.26B |
| Net Income (Most Recent Fiscal Year) | $858.98M |
| PE Ratio (Current Year Earnings Estimate) | 7.97 |
| PE Ratio (Trailing 12 Months) | 8.28 |
| PEG Ratio (Long Term Growth Estimate) | 2.37 |
| Price to Sales Ratio (Trailing 12 Months) | 9.19 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.23 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 8.66 |
| Pre-Tax Margin (Trailing 12 Months) | 72.19% |
| Net Margin (Trailing 12 Months) | 44.23% |
| Return on Equity (Trailing 12 Months) | 25.54% |
| Return on Assets (Trailing 12 Months) | 14.11% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.26 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.26 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.74 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $17.56 |
| Earnings per Share (Most Recent Fiscal Quarter) | $1.14 |
| Earnings per Share (Most Recent Fiscal Year) | $4.13 |
| Diluted Earnings per Share (Trailing 12 Months) | $1.73 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 583.17M |
| Free Float | 472.95M |
| Market Capitalization | $21.20B |
| Average Volume (Last 20 Days) | 2.94M |
| Beta (Past 60 Months) | 0.55 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 18.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 54.35% |
| Annual Dividend (Based on Last Quarter) | $0.88 |
| Dividend Yield (Based on Last Quarter) | 2.42% |